Charles F. Wagner Jr., EVP & CFO, has demonstrated a consistent pattern of selling activity in Vertex Pharmaceuticals (VRTX) shares over the past two years, with minimal buying. Since 2024, Wagner has executed 28 transactions totaling $30.58 million in sales against just $1.81 million in purchases—a nearly 17:1 sell-to-buy ratio by dollar value. His most recent disposals include five sales in early 2026, with transactions on February 10 ($1.43 million), February 13 ($2.23 million), February 17 ($1.11 million), and February 24 ($846,031), all coded as "F" for tax liability sales. The only notable buy occurred on January 6, 2026, when Wagner acquired $1.81 million in shares through an "M"-coded market purchase.
Wagner’s selling has been concentrated around annual tax seasons, with multi-million-dollar transactions in February 2024, February 2025, and February 2026—each involving multiple sales totaling between $5.3 million and $6.3 million per year. His largest single sale was a $4.39 million disposition on January 6, 2026, followed by a $3.16 million sale in December 2025. While the "F"-coded transactions suggest routine tax-related sales, the absence of offsetting buys beyond the January 2026 purchase indicates a net reduction in his VRTX position over time. All activity has been confined to Vertex, where he serves as CFO, with no trades in other securities.
AI-assisted summary